CERVARIX(R) U.S. Regulatory Update

- GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine

PHILADELPHIA and LONDON, March 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline
(NYSE: GSK) today provided the following update regarding its application to
the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its
vaccine to prevent cervical cancer and cervical pre-cancer related to human
papillomavirus types 16 and 18.

GSK has submitted final data from its Phase III pivotal efficacy study,
HPV-008, to the FDA. The FDA has previously reviewed interim data from the
same trial. FDA review of this type of Biologics License Application (BLA)
submission is expected to take six months, according to agency regulations.

"We are pleased to have reached this significant milestone for CERVARIX(R).
The data submitted to the FDA reaffirm our confidence in the vaccine's safety
and efficacy profile," said Barbara Howe, M.D., Vice President and Director,
North American Vaccine Development, GlaxoSmithKline. "We will continue working
closely with the FDA in order to make this vaccine available to help protect
the cervical health of girls and women in the U.S."

HPV-008 is a Phase III clinical study of more than 18,600 women between 15-25
years of age, from 14 countries across Europe, Asia-Pacific and Latin and
North America. The primary objective was to assess vaccine efficacy in the
prevention of high-grade pre-cancerous cervical lesions (CIN2+) caused by
human papillomavirus types 16 or 18. Secondary objectives included evaluation
of vaccine efficacy in the prevention of pre-cancerous cervical lesions
(CIN1+) and infections caused by virus types 16 or 18 or other cancer-causing
virus types, as well as immune response and safety. GSK will submit the data
to a peer-reviewed journal in the coming months.

The BLA for the vaccine includes safety, efficacy and immune response data
from clinical trials in nearly 30,000 females and reflects an ethnically
diverse population.

To date, GSK's vaccine has been approved in more than 90 countries around the
world including the 27 member countries of the European Union, Mexico,
Australia, Singapore and the Philippines. Licensing applications have been
submitted in more than 20 additional countries including Japan. GSK also
submitted the vaccine to the World Health Organization (WHO) for
prequalification in September 2007.

Notes to Editors
Cervical Health Facts - Worldwide, every two minutes a woman dies of cervical
cancer; each year more than 500,000 women will be newly diagnosed and more
than 280,000 women will die. In the U.S., after breast cancer, cervical
cancer is the leading cause of cancer-related death in women between the ages
of 20 to 39 in the United States. Also, in the U.S. each year there are an
estimated 3.5 million abnormal Pap smears, and more than 1.5 million
precancerous lesions are diagnosed.

GlaxoSmithKline Biologicals - GSK's vaccines business is one of the world's
leading vaccine companies and a leader in innovation. The company is active in
the fields of vaccine research, development and production with over 30
vaccines approved for marketing and 20 more in development. Headquartered in
Belgium, GSK Biologicals has 13 manufacturing sites strategically positioned
around the globe. In 2008 GSK Biologicals distributed 1.1 billion doses of
vaccines to 176 countries in both the developed and the developing world - an
average of 3 million doses a day. Through its accomplished and dedicated
workforce, GSK Biologicals applies its expertise to discover innovative
vaccines that contribute to the health and well-being of people of all
generations around the world.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For further
information please visit www.gsk.com.

CERVARIX(R) is a registered trademark of the GlaxoSmithKline group of
companies.

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, GSK cautions investors that any forward-looking statements
or projections made by GSK, including those made in this announcement, are
subject to risks and uncertainties that may cause actual results to differ
materially from those projected. Factors that may affect GSK' s operations are
described under 'Risk Factors' in the 'Business Review' in the company' s
Annual Report on Form 20-F for 2008.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

SOURCE GlaxoSmithKline

UK Media, Philip Thomson, David Outhwaite, or Stephen Rea, all at
+020-8047-5502; or US Media, Nancy Pekarek, Mary Anne Rhyne, Kevin Colgan, or
Sarah Alspach, all at +1-919-483-2839; or European Analysts-Investors, David
Mawdsley, +020-8047-5564, Sally Ferguson, +020-8047-5543, or Gary Davies,
+020-8047-5503; or US Analysts-Investors, Tom Curry, +1-215-751-5419, or Jen
Hill-Baxter, +1-215-751-7002, all of GlaxoSmithKline